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Background: Misplacement during percutaneous aortic valve implantation can be
associated with severe complications. The DFM valve is repositionable and retrievable,
however, the non metallic inflatable and conformable design of the valve results in
less radial force which may have an impact on stability and valve function over time.
We therefore analyzed the mid-term stability of the position, shape and hemodynamic
performance of the Direct Flow Medical (DFM) percutaneous aortic valve.
Methods: Sixteen symptomatic high-risk for surgery patients (pts) with aortic stenosis
and a logistic Euroscore > 20 were implanted and the subject of this analysis. Clinical,
echocardiographic and Dual Source Multislice Computed Tomography (DSMCT) were
obtained during 2 year follow up.
Results: The 1- and 2- year survival rates were 81.3 and 68.7%, respectively. DSMCT
follow up indicated no changes in position, diameter, and orifice area of the DFM valve
over time. Echocardiography revealed a significant decrease of the mean gradient from
baseline (50.1±11.3 mmHg) to 30 days (19.6±5.7 mmHg, p < 0.001) which remained
stable over 2 years. The aortic valve area increased from 0.57 ± 0.15 cm2 at baseline
to 1.47 ± 0.35 cm2 at 30 days (p < 0.001) and did not significantly change during 2
year follow-up. 73% of pts had no aortic regurgitation, 27 % had minimal paravalvular
aortic regurgitation.
Conclusion: Two year follow up data of the nonmetallic, repositionable and retrievable
DFM valve show stability of the position, shape and hemodynamic performance with
no paravalvular aortic regurgitation in the majority of patients.
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Background: Left atrium diameter (LAD) is an independent predictor for
cardiovascular events in patients with dilated or hypertrophic cardiomyopathy. This
study was undertaken to investigate the relationship among an abnormal LAD, aortic
valve area, clinical events, and the impact of aortic valve replacement on LAD in a
population with severe aortic stenosis (AS).
Methods: We investigated 530 patients with severe AS. Each patient underwent a TTE
with a standardized measurement of the LAD. Patients with moderate or severe mitral
regurgitation were excluded. Patients were divided into 3 groups based on their LAD.
Group I: LAD <4cm (n=124; 24%), group II: LAD 4-4,9cm (n=278; 52%) and group
III: LAD >5cm (n=128, 24%).
Results: Patients with an abnormal LAD (group III) had a higher incidence of heart
failure, including higher rate of BNP, pulmonary hypertension and a significant lower
ejection fraction. (Table 1) Atrial fibrillation was documented in 49.2% in group III as
compared to 20.3% and 27.9% in groups I and II, respectively with p <0.001. No
significant differences were found regarding the aortic valve area among the 3 groups
(p=0.430). LAD had moderate correlation with ejection fraction (r=-0.2, p <0.001),
pulmonary pressure (r=0.23, p <0.001) and with pulmonary capillary wedge pressure
(r=0.31, p <0.001). There was no correlation between LAD and aortic valve area (r=-
0.03, p= 0.48). There was no significant difference in mortality among the three groups.
(Figure 1) There was no significant reduction in LAD for any of the groups after T-
AVR: 5.21cm±0.6 vs. 5.23cm±0.57, p=0.75 and surgical AVR: 5.34cm±0.39
vs.5.37cm±0.98, p=0.97.
Conclusion: The treatment of aortic stenosis either by T-AVR or surgical AVR does
not reduce the LAD immediately post procedure. Large LAD in patients with severe
aortic stenosis is associated with heart failure and arrhythmia but not with the severity
of the aortic stenosis.
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Background: Transcatheter Aortic Valve Replacement (TAVR)may offer advanced
therapeutic options to patients with symptomatic aortic stenosis. After the publication
of PARTNERS cohort B, there is a growing interest in TAVR within institutions.
Societies recommended that an annual volume of 24 cases would be considered
reasonable and greater than 50 would be ideal. The aim of this study was to determine
from a tertiary care academic referral center, the volume of symptomatic aortic stenosis
(AS) patients fulfilling the PARTNERS B criteria.
Methods: Between 1/2008 and 12/2010, 33,543 echocardiograms in 21,652 patients
were retrospectively evaluated. Patients with any grade AS as graded in the final echo
report were identified and stratified by severity. Manual inpatient and outpatient chart
audits were performed to evaluate the presence of symptoms, specifically syncope,
angina or dyspnea consistent with NYHA class II congestive heart failure. Nonsurgical
candidates were evaluated for demographics, STS and Euroscore, and cross referenced
with the PARTNER cohort B exclusion criteria to determine potential eligibility for
TAVR.
Results: AS was identified in 833 patients (3.8%). Among them, moderate to severe
and severe AS was present in 192 patients (23%) of which 146 were symptomatic
(76%), with 65% considered surgical candidates. The average age in the nonsurgical
group was 81 years, 42% male, 48% diabetic, mean creatinine of 1.7, STS risk of
mortality of 7.9% + 6.2%, morbidity and mortality of 33.8% + 13.3% and logistic
Euroscore of 11.06% + 3%. Among the nonsurgical, after exclusions, only 15% met
PARTNERS criteria. (Figure).
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